Cingulate Inc. Files 8-K Report
Ticker: CINGW · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1862150
| Field | Detail |
|---|---|
| Company | Cingulate Inc. (CINGW) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: CING
TL;DR
Cingulate Inc. filed an 8-K, likely with financial updates. Stay tuned.
AI Summary
On January 7, 2025, Cingulate Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This 8-K filing indicates Cingulate Inc. is providing updated information to the SEC, which could include material events or financial updates relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications detailed in the provided text.
Key Players & Entities
- Cingulate Inc. (company) — Registrant
- January 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Kansas City, KS 66205 (location) — Address of principal executive offices
- (913) 942-2300 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Cingulate Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, reporting on January 7, 2025, and includes information on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is Cingulate Inc.'s state of incorporation?
Cingulate Inc. is incorporated in Delaware.
What is the principal executive office address for Cingulate Inc.?
The address is 1901 W. 47th Place, Kansas City, KS 66205.
What is the registrant's telephone number?
The registrant's telephone number is (913) 942-2300.
What is the SIC code for Cingulate Inc.?
The Standard Industrial Classification code for Cingulate Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-07 07:35:22
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 24KB
- 0001493152-25-001113.txt ( ) — 292KB
- cing-20250107.xsd (EX-101.SCH) — 4KB
- cing-20250107_def.xml (EX-101.DEF) — 29KB
- cing-20250107_lab.xml (EX-101.LAB) — 36KB
- cing-20250107_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On January 7, 2025, the Company announced that it had completed its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidate) for the treatment of ADHD. No serious adverse events were reported. A data readout regarding bioavailability with or without food is expected in the second quarter of 2025. A New Drug Application submission with the FDA is targeted for mid-2025. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CINGULATE INC. Dated: January 7, 2025 By: /s/ Shane J. Schaffer Name: Shane J. Schaffer Title: Chief Executive Officer